{"id":"nct:NCT04929249","kind":"trial","title":"A Randomized Study to Evaluate the Effect of an \"Inclisiran First\" Implementation Strategy Compared to Usual Care in Patients With Atherosclerotic Cardiovascular Disease and Elevated LDL-C Despite Receiving Maximally Tolerated Statin Therapy (VICTORION-INITIATE)","authors":["Novartis Pharmaceuticals"],"author_count":1,"year":2021,"published":"2021-06-18","venue":"ClinicalTrials.gov","cited_by":null,"doi":null,"arxiv_id":null,"nct_id":"NCT04929249","source_url":"https://clinicaltrials.gov/study/NCT04929249","archive_url":"https://space-kitty.com/papers/nct:NCT04929249","updated":"2025-05-16","pmid":null,"pmcid":null,"openalex_id":null,"pdf_url":null,"abstract":"The purpose of this study was to assess the effectiveness of an \"inclisiran first\" implementation strategy (addition of inclisiran to maximally tolerated statin therapy immediately upon failure to achieve acceptable LDL-C with maximally tolerated statin therapy alone) compared to usual care in an atherosclerotic cardiovascular disease (ASCVD) population.","abstract_license":"ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters","license":"ClinicalTrials.gov terms (attribution, processing date, modifications noted)","is_open_access":true,"retracted":false,"peer_reviewed":null,"categories":["Atherosclerotic Cardiovascular Disease"],"details":{"acronym":"V-INITIATE","status":"COMPLETED","phase":"PHASE3","study_type":"INTERVENTIONAL","enrollment":450,"sponsor":"Novartis Pharmaceuticals","conditions":["Atherosclerotic Cardiovascular Disease"],"interventions":["DRUG: Inclisiran"],"start_date":"2021-06-25","start_date_type":"ACTUAL","primary_completion_date":"2023-09-15","has_results":true,"data_source":"ClinicalTrials.gov","data_processed":"2026-10-29T09:00:05","modifications":"selected fields only; whitespace normalized; brief summary truncated to 2,000 characters"},"provenance":"clinicaltrials","attribution":"Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.","topics":[{"slug":"cardiovascular-innovation","name":"Cardiovascular Therapeutics","domain_slug":"medicine"}],"cited_in_dossiers":[]}